Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | ESR1 | P03372 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TUBB4A | P04350 | 5/20 | 0.39 |
| ▸ | TUBB | P07437 | 5/20 | 0.39 |
| ▸ | TUBA3C | P0DPH7 | 5/20 | 0.39 |
| ▸ | TUBA1B | P68363 | 5/20 | 0.39 |
| ▸ | TUBA4A | P68366 | 5/20 | 0.39 |
| ▸ | TUBB4B | P68371 | 5/20 | 0.39 |
| ▸ | TUBB3 | Q13509 | 5/20 | 0.39 |
| ▸ | TUBB2A | Q13885 | 5/20 | 0.39 |
| ▸ | TUBB8 | Q3ZCM7 | 5/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL805039 | 0.85 | PDGFRB (0.51) | NPSR1SMN1; SMN2TP53TUBB4ATUBB | |
| SCHEMBL25478448 | 0.80 | NPSR1 (0.41) | NPSR1SMN1; SMN2TP53ESR1KDM4E | |
| SCHEMBL25478962 | 0.79 | ESR1 (0.41) | NPSR1SMN1; SMN2TP53ESR1KDM4E | |
| SCHEMBL25478450 | 0.77 | EGFR (0.42) | NPSR1SMN1; SMN2TP53KDM4EALDH1A1 | |
| SCHEMBL12130393 | 0.74 | PDGFRB (0.43) | SMN1; SMN2ALDH1A1MEN1MAPTRAB9A | |
| SCHEMBL12130390 | 0.72 | PDE4D (0.52) | SMN1; SMN2KDM4EALDH1A1MEN1MAPT | |
| SCHEMBL12130436 | 0.71 | CYP3A4 (0.43) | SMN1; SMN2TP53ALDH1A1MEN1MAPT | |
| SCHEMBL786569 | 0.71 | TUBB4A (0.55) | MEN1RAB9AKMT2ATUBB4ATUBB | |
| SCHEMBL12130376 | 0.70 | ALDH1A1 (0.45) | NPSR1SMN1; SMN2KDM4EALDH1A1MAPT | |
| SCHEMBL424789 | 0.69 | SMO (0.63) | NPSR1SMN1; SMN2TP53TUBB4ATUBB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230321045-A1 | METHODS OF TREATING INFLUENZA AND POXVIRUS VIRAL INFECTIONS | VERU INC. (US) | 2023-10-12 | — | — | US | disclosed |
| US-20230265081-A1 | METHODS OF TREATING CORONAVIRUS | VERU INC. (US) | 2023-08-24 | — | — | US | disclosed |
| US-11648236-B2 | Methods of treating coronavirus | VERU INC. (US) | 2023-05-16 | — | — | US | disclosed |
| US-20170226086-A1 | COMPOUNDS FOR TREATMENT OF CANCER | GTx. Inc. (US) | 2017-08-10 | — | — | US | disclosed |
| US-9447049-B2 | Compounds for treatment of cancer | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2016-09-20 | — | — | US | disclosed |
| US-8822513-B2 | Compounds for treatment of cancer | GTX, INC. (US) | 2014-09-02 | — | — | US | disclosed |
| US-20130197049-A1 | COMPOUNDS FOR TREATMENT OF CANCER | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2013-08-01 | — | — | US | disclosed |
| US-20120071524-A1 | COMPOUNDS FOR TREATMENT OF CANCER | ONCTERNAL THERAPEUTICS, INC | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071524-A1 | COMPOUNDS FOR TREATMENT OF CANCER | KLK3, BRDT, ACP3 | NPSR1 3755/4885SMN1; SMN2 3816/4885TP53 4/4885 |
| US-20130197049-A1 | COMPOUNDS FOR TREATMENT OF CANCER | KLK3, BRDT, ACP3 | NPSR1 3755/4885SMN1; SMN2 3816/4885TP53 4/4885 |
| US-20230321045-A1 | METHODS OF TREATING INFLUENZA AND POXVIRUS VIRAL INFECTIONS | TUBB3, TUBB1, TUBB | NPSR1 3390/4885SMN1; SMN2 3405/4885TP53 692/4885 |
| US-20230265081-A1 | METHODS OF TREATING CORONAVIRUS | TUBB3, TUBB1, TUBB | NPSR1 3717/4885SMN1; SMN2 2823/4885TP53 1287/4885 |
| US-20170226086-A1 | COMPOUNDS FOR TREATMENT OF CANCER | KLK3, BRDT, ACP3 | NPSR1 3755/4885SMN1; SMN2 3816/4885TP53 4/4885 |
| US-11648236-B2 | Methods of treating coronavirus | TUBB3, TUBB1, TUBB | NPSR1 3717/4885SMN1; SMN2 2823/4885TP53 1287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.